DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second quarter 2026
DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its first quarter 2026 financial
LOS ANGELES, April 20, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Instil Bio, Inc., ("Instil" or the "Company") (NASDAQ:TIL) investors that the firm has initiated an investigation into possible
Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of strategic development Cash position of $76.3 million as of December 31, 2025 expected to fund current operating plan beyond
NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ:TIL). Such investors are advised to contact
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ:TIL). Such investors are advised to contact Danielle
NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ:TIL). Such investors are advised to contact
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ:TIL). Such investors are advised to contact
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ:TIL). Such investors are advised to contact
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ:TIL). Such investors are advised to contact Danielle
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ:TIL). Such investors are advised to contact
DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (NASDAQ:TIL) ("Instil") today announced that Axion Bio, Inc. ("Axion"), a wholly-owned subsidiary of Instil, has decided to discontinue clinical development of
DALLAS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its third quarter 2025
ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scores Differentiated structure of ‘2510 potentially results in best-in-class monotherapy activity in 2L+ NSCLC for PD-(L)1xVEGF
With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 ("‘2510") anticipated before the end of 2025 Updated ‘2510 monotherapy data in squamous-NSCLC to be presented at IASLC's 2025
